{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:00:11Z","timestamp":1778878811038,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T00:00:00Z","timestamp":1367539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s13277-013-0814-z","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T05:29:57Z","timestamp":1367472597000},"page":"2645-2650","source":"Crossref","is-referenced-by-count":47,"title":["The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients"],"prefix":"10.1007","volume":"34","author":[{"given":"Beyhan","family":"Omer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema","family":"Genc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozguc","family":"Takmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Dirican","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Kusku-Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinan","family":"Berkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Figen","family":"Gurdol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,3]]},"reference":[{"key":"814_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71\u201396.","journal-title":"CA Cancer J Clin"},{"key":"814_CR2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crad.2006.06.015","volume":"62","author":"SA Sohaib","year":"2007","unstructured":"Sohaib SA, Houghton SL, Meroni R, et al. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007;62:28\u201334.","journal-title":"Clin Radiol"},{"key":"814_CR3","first-page":"479","volume":"92","author":"SL Rose","year":"2004","unstructured":"Rose SL, Bradley SL, Lutgendorf SK, Sorosky J, Anderson B. The impact of adjuvant radiation therapy on long-term quality of life in patients with stage I endometrial cancer. Gynecol Oncol. 2004;92:479\u201380.","journal-title":"Gynecol Oncol"},{"key":"814_CR4","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2165\/00003495-200161100-00003","volume":"61","author":"BM Southcott","year":"2001","unstructured":"Southcott BM. Carcinoma of the endometrium. Drugs. 2001;61:1395\u2013405.","journal-title":"Drugs"},{"key":"814_CR5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1289\/ehp.94102306","volume":"102","author":"E Taioli","year":"1994","unstructured":"Taioli E, Kinney P, Zhitkovich A, et al. Application of reliability models to studies of biomarker validation. Environ Health Perspect. 1994;102:306\u20139.","journal-title":"Environ Health Perspect"},{"key":"814_CR6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1477-7827-1-49","volume":"1","author":"AA Arslan","year":"2003","unstructured":"Arslan AA, Zeleniuch-Jacquotte A, Lukanova A, et al. Reliability of follicle-stimulating hormone measurements in serum. Reprod Biol Endocrinol. 2003;1:49.","journal-title":"Reprod Biol Endocrinol"},{"key":"814_CR7","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0277-5379(88)90113-7","volume":"24","author":"Y Touitou","year":"1988","unstructured":"Touitou Y, Bogdan A. Tumor markers in non-malignant diseases. Eur J Cancer Clin Oncol. 1988;24:1083\u201391.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"814_CR8","first-page":"283","volume":"1","author":"A Gadducci","year":"1990","unstructured":"Gadducci A, Ferfeghini M, Prontera C, et al. A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical cancer. Eur J Gynaecol Oncol. 1990;1:283\u20138.","journal-title":"Eur J Gynaecol Oncol"},{"key":"814_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.2002.6664","volume":"86","author":"CH Hsieh","year":"2002","unstructured":"Hsieh CH, ChangChien CC, Lin H, et al. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol. 2002;86:28\u201333.","journal-title":"Gynecol Oncol"},{"key":"814_CR10","first-page":"585","volume":"50","author":"JL Powell","year":"2005","unstructured":"Powell JL, Hill KA, Shiro BC, Diehl SJ, Gajewski WH. Preoperative CA 125 levels in treating endometrial cancer. J Reprod Med. 2005;50:585\u201390.","journal-title":"J Reprod Med"},{"key":"814_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2007.05.041","volume":"107","author":"Z Yurkovetsky","year":"2007","unstructured":"Yurkovetsky Z, Ta\u2019asan S, Skates S, et al. Development of multi-marker panel for early detection of endometrial cancer: High diagnostic power of prolactin. Gynecol Oncol. 2007;107:58\u201365.","journal-title":"Gynecol Oncol"},{"key":"814_CR12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown A, Miller M, Skaters S, Allard W, Verch T, et al. The use of multiple novel biomarkers for the detection of ovarian carcinoma in patients with pelvic mass. Gynecol Oncol. 2008;108:402\u20138.","journal-title":"Gynecol Oncol"},{"key":"814_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1465-9921-7-61","volume":"7","author":"L Bingle","year":"2006","unstructured":"Bingle L, Cross SS, High AS, Wallace WA, Rassl D, Yuan G, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;7:61.","journal-title":"Respir Res"},{"key":"814_CR14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is over expressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162\u20139.","journal-title":"Cancer Res"},{"key":"814_CR15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hiissa J, Huvila J, Kujari H, Stala M, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315\u20139.","journal-title":"Br J Cancer"},{"key":"814_CR16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19","author":"M Galgano","year":"2006","unstructured":"Galgano M, Hampton G, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847\u2013553.","journal-title":"Mod Pathol"},{"key":"814_CR17","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2011.109","volume":"104","author":"E Bignotti","year":"2011","unstructured":"Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011;104:1418\u201325.","journal-title":"Br J Cancer"},{"key":"814_CR18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1515\/cclm-2011-0757","volume":"50","author":"L Zanotti","year":"2012","unstructured":"Zanotti L, Bignotti E, Calza S, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012;50:2189\u201398.","journal-title":"Clin Chem Lab Med"},{"key":"814_CR19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2012.04.022","volume":"126","author":"I Mutz-Dehbalaie","year":"2012","unstructured":"Mutz-Dehbalaie I, Egle D, Fessler S, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012;126:186\u201391.","journal-title":"Gynecol Oncol"},{"key":"814_CR20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2009.10.050","volume":"115","author":"DG Mutch","year":"2009","unstructured":"Mutch DG. The New FIGO staging system for cancers of the vulva, cervix, endometrium, and sarcomas. Gynecol Oncol. 2009;115:325\u20138.","journal-title":"Gynecol Oncol"},{"key":"814_CR21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/cancers2021312","volume":"2","author":"Y Ueda","year":"2010","unstructured":"Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshino K, Fujita M, et al. Serum biomarkers for early detection of gynecologic cancers. Cancer. 2010;2:1312\u20137.","journal-title":"Cancer"},{"key":"814_CR22","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom I, Raycraft J, Hayden-Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695\u2013700.","journal-title":"Cancer Res"},{"key":"814_CR23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0029-7844(97)00286-X","volume":"90","author":"AK Sood","year":"1997","unstructured":"Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA 125 level in the management of uterine cancer and prediction of outcome. Obstet Gynecol. 1997;90:441\u20137.","journal-title":"Obstet Gynecol"},{"key":"814_CR24","first-page":"1897","volume":"18","author":"NP Koper","year":"1998","unstructured":"Koper NP, Massuger LF, Thomas CM, Kiemeney LA, Verbeek AL. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Res. 1998;18:1897\u2013902.","journal-title":"Anticancer Res"},{"key":"814_CR25","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/00016340601022777","volume":"85","author":"HH Chung","year":"2006","unstructured":"Chung HH, Kim JW, Park NH, Song YS, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol. 2006;85:1501\u20135.","journal-title":"Acta Obstet Gynecol"},{"key":"814_CR26","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-03-0787","volume":"10","author":"GJ Rustin","year":"2004","unstructured":"Rustin GJ, Bast RC, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004;10:3919\u201326.","journal-title":"Clin Cancer Res"},{"key":"814_CR27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","volume":"9","author":"J Li","year":"2009","unstructured":"Li J, Dowdy S, Tipton T, Podratz K, Lu W-G, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009;9:555\u201366.","journal-title":"Expert Rev Mol Diagn"},{"key":"814_CR28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s13277-012-0356-9","volume":"33","author":"K Iwahori","year":"2012","unstructured":"Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara R, Okamoto N, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol. 2012;33:1141\u20139.","journal-title":"Tumour Biol"},{"key":"814_CR29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3802\/jgo.2009.20.3.181","volume":"20","author":"S-C Yoo","year":"2009","unstructured":"Yoo S-C, Yoon J-H, Kim WY, Chang S-J, Joo H-J, Ryu G-S. Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery. J Gynecol Oncol. 2009;20:181\u20136.","journal-title":"J Gynecol Oncol"},{"key":"814_CR30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/gyno.1994.1093","volume":"53","author":"T Alagoz","year":"1994","unstructured":"Alagoz T, Buller RE, Berman M, et al. What is normal CA 125 level? Gynecol Oncol. 1994;53:93\u20137.","journal-title":"Gynecol Oncol"},{"key":"814_CR31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S1701-2163(16)34657-6","volume":"32","author":"A Sebastianelli","year":"2010","unstructured":"Sebastianelli A, Renaud MC, Gregorie J, Roy M, Plante M. Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can. 2010;32:856\u201360.","journal-title":"J Obstet Gynaecol Can"},{"key":"814_CR32","doi-asserted-by":"crossref","first-page":"228e1","DOI":"10.1016\/j.ajog.2010.03.043","volume":"203","author":"RG Moore","year":"2010","unstructured":"Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller C, Allard WJ, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with pelvic mass. Am J Obstet Gynecol. 2010;203:228e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"814_CR33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cncr.24838","volume":"116","author":"E Cocco","year":"2010","unstructured":"Cocco E, Bellone S, El-Sahwi K, et al. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer. 2010;116:843\u201351.","journal-title":"Cancer"},{"key":"814_CR34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cncr.20377","volume":"101","author":"N Khan","year":"2004","unstructured":"Khan N, Cromer CJ, Campa M, Patz Jr EF. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for detection of nonsmall cell lung carcinoma. Cancer. 2004;101:379\u201384.","journal-title":"Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-0814-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-013-0814-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-0814-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T04:42:20Z","timestamp":1562992940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-013-0814-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,3]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s13277-013-0814-z","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,3]]}}}